Novel systemic therapeutic for nasopharyngeal carcinoma

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Chan, Stephen L ^a   Ma, Brigette B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiogenesis; Epidermal growth factor receptor; Epigenetic; Nasopharyngeal cancer

Indexed keywords

AZACITIDINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PAZOPANIB; SORAFENIB; SUNITINIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLEEDING; CARCINOMA CELL; DIGESTIVE SYSTEM HEMORRHAGE; DRUG TARGETING; EPIGENETICS; EPISTAXIS; EPSTEIN BARR VIRUS; HEMATEMESIS; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LOADING DRUG DOSE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NONHUMAN; RADIATION DERMATITIS; REVIEW; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84857520595     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.635646     Document Type: Review

References (47)

1. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002;13:1007-15
2. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007;9:1-24 (Pubitemid 47398642)
3. Ali H, al-Sarraf M. Chemotherapy in advanced nasopharyngeal cancer. Oncology (Williston Park) 2000;14:1223-30; discussion 1232-1237, 1239-1242
4. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997;350:1087-91 (Pubitemid 27437868)
5. Ma BB, Chan AT. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther 2006;6:383-94 (Pubitemid 44192920)
6. Ma B, Poon T, To KF, et al. Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma. Head Neck 2003;25:864-72
7. Hui AB, Lo KW, Teo PM, et al. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 2002;20:467-73
8. Ma BB, Lui VW, Poon FF, et al. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs 2010;28:326-33
9. Yip WK, Leong VC, Abdullah MA, et al. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 2008;19:319-28 (Pubitemid 351176090)
10. Ma BB, Lui VW, Hui EP, et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs 2010;28:413-20
11. Or YY, Hui AB, To KF, et al. PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer 2006;118:1065-7
12. Lee SC, Lim SG, Soo R, et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics 2006;16:73-4 (Pubitemid 41803879)
13. Chou CC, Chou MJ, Tzen CY. PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol 2009;26:322-6
14. Sung FL, Poon TC, Hui EP, et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo 2005;19:237-45
15. Hsu CH, Gao M, Chen CL, et al. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology 2005;68:538-47 (Pubitemid 41160987)
16. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-76
17. Ma BB, Leung SF, Kam MK, et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 2008;26(20 Suppl):abstract 6055
18. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038-44 (Pubitemid 34408793)
19. Chua DT, Wei WI, Wong MP, et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008;30:863-7 (Pubitemid 352008945)
20. Ma B, Hui EP, King A, et al. A phase II study of gefitinib in patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol 2008;62:59-64 (Pubitemid 351537846)
21. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814 (Pubitemid 29411709)
22. Guang-Wu H, Sunagawa M, Jie-En L, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 2000;110:2066-9
23. Wakisaka N, Wen QH, Yoshizaki T, et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope 1999;109:810-14 (Pubitemid 29227932)
24. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-604 (Pubitemid 34856346)
25. Rubio L, Burgos JS, Morera C, et al. Morphometric study of tumor angiogenesis as a new prognostic factor in nasopharyngeal carcinoma patients. Pathol Oncol Res 2000;6:210-16
26. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001;98:6905-10 (Pubitemid 32538315)
27. Qian CN, Min HQ, Lin HL, et al. Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol 1998;112:849-53
28. Qian CN, Min HQ, Lin HL, et al. Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/HK1. Oncology 1999;57:36-41
29. Hui EP, Lui VW, Wong CS, et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs 2011;29:1123-31
30. Hui EP, Ma BB, King AD, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011;22:1280-7
31. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766-73 (Pubitemid 47372619)
32. Lee NY, Zhang QE, Garden AS, et al. Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): preliminary clinical results of RTOG 0615. J Clin Oncol 2011;29(Suppl):abstract 5516
33. Lim WT, Thng C, Toh CK, et al. A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma. J Clin Oncol 2010;28(15S):abstract 5556
34. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28 (Pubitemid 34587077)
35. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74 (Pubitemid 30169152)
36. Fuks F, Burgers WA, Brehm A, et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24:88-91 (Pubitemid 30041428)
37. Kuzmichev A, Reinberg D. Role of histone deacetylase complexes in the regulation of chromatin metabolism. Curr Top Microbiol Immunol 2001;254:35-58
38. Kwong J, Lo KW, To KF, et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002;8:131-7 (Pubitemid 34101468)
39. Chan SL, Cui Y, van Hasselt A, et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest 2007;87:644-50 (Pubitemid 46920100)
40. Countryman JK, Gradoville L, Miller G. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. J Virol 2008;82:4706-19 (Pubitemid 351657033)
41. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006;66:8762-9 (Pubitemid 44449193)
42. Chan AT, Tao Q, Robertson KD, et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 2004;22:1373-81 (Pubitemid 41103618)
43. Phase I Study of Vorinostat (SAHA) and Azacitidine in Patients With Locally Recurrent or Metastatic Nasopharyngeal Carcinoma or Nasal Type Natural Killer (NK)/T-Cell Lymphoma. Bethesda, MD: National Cancer Institute, 2006: NCT00336063. Available from: http://www.cancer.gov/clinicaltrials/search/view? cdrid=472702&version=Health Professional&protocolsearchid=9687041 [Last accessed 26 October 2011]
44. Ma BB, Lui VW, Poon FF, et al. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs 2010;28:326-33
45. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36 (Pubitemid 41094421)
46. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40 (Pubitemid 34525728)
47. Kornblith AB, Herndon JE II, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;20:2441-52 (Pubitemid 34525729)